Boston Trust Walden Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Boston Trust Walden Corp lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 196,145 shares of the medical research company's stock after selling 4,169 shares during the quarter. Boston Trust Walden Corp owned 0.38% of Charles River Laboratories International worth $38,635,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund increased its holdings in shares of Charles River Laboratories International by 1.0% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock valued at $914,000 after purchasing an additional 45 shares in the last quarter. American Trust grew its position in Charles River Laboratories International by 5.9% during the second quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after buying an additional 54 shares during the period. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after buying an additional 57 shares in the last quarter. OLD National Bancorp IN lifted its position in shares of Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock valued at $392,000 after acquiring an additional 59 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC boosted its stake in shares of Charles River Laboratories International by 2.0% during the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company's stock worth $652,000 after acquiring an additional 62 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 0.3 %

Shares of CRL stock traded down $0.61 during mid-day trading on Friday, hitting $182.12. 501,310 shares of the company's stock were exchanged, compared to its average volume of 601,626. The stock has a market cap of $9.38 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 5.11 and a beta of 1.36. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The stock has a 50-day simple moving average of $195.84 and a two-hundred day simple moving average of $211.08.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Equities analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International declared that its board has authorized a share buyback program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

Analyst Ratings Changes

Several research firms recently weighed in on CRL. StockNews.com raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, October 16th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $270.00 to $205.00 in a research report on Thursday, August 8th. UBS Group lowered their price objective on shares of Charles River Laboratories International from $290.00 to $240.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research report on Friday, September 20th. Finally, Barclays lowered their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $209.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).